JP7381578B2 - ヒストンデアセチラーゼの二環式阻害剤 - Google Patents

ヒストンデアセチラーゼの二環式阻害剤 Download PDF

Info

Publication number
JP7381578B2
JP7381578B2 JP2021523577A JP2021523577A JP7381578B2 JP 7381578 B2 JP7381578 B2 JP 7381578B2 JP 2021523577 A JP2021523577 A JP 2021523577A JP 2021523577 A JP2021523577 A JP 2021523577A JP 7381578 B2 JP7381578 B2 JP 7381578B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
stirred
etoac
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531335A (ja
Inventor
フラー，ネイサン・オリバー
ロウ，ジョン・エイ，ザ・サード
Original Assignee
アルカーメス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカーメス，インコーポレイテッド filed Critical アルカーメス，インコーポレイテッド
Publication of JP2021531335A publication Critical patent/JP2021531335A/ja
Priority to JP2023187395A priority Critical patent/JP2024012457A/ja
Application granted granted Critical
Publication of JP7381578B2 publication Critical patent/JP7381578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021523577A 2018-07-13 2019-07-12 ヒストンデアセチラーゼの二環式阻害剤 Active JP7381578B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023187395A JP2024012457A (ja) 2018-07-13 2023-11-01 ヒストンデアセチラーゼの二環式阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697497P 2018-07-13 2018-07-13
US62/697,497 2018-07-13
PCT/US2019/041587 WO2020014602A1 (en) 2018-07-13 2019-07-12 Bicyclic inhibitors of histone deacetylase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023187395A Division JP2024012457A (ja) 2018-07-13 2023-11-01 ヒストンデアセチラーゼの二環式阻害剤

Publications (2)

Publication Number Publication Date
JP2021531335A JP2021531335A (ja) 2021-11-18
JP7381578B2 true JP7381578B2 (ja) 2023-11-15

Family

ID=67480367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523577A Active JP7381578B2 (ja) 2018-07-13 2019-07-12 ヒストンデアセチラーゼの二環式阻害剤
JP2023187395A Withdrawn JP2024012457A (ja) 2018-07-13 2023-11-01 ヒストンデアセチラーゼの二環式阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023187395A Withdrawn JP2024012457A (ja) 2018-07-13 2023-11-01 ヒストンデアセチラーゼの二環式阻害剤

Country Status (15)

Country Link
US (1) US20210276977A1 (zh)
EP (1) EP3820863A1 (zh)
JP (2) JP7381578B2 (zh)
KR (1) KR20210031703A (zh)
CN (1) CN112805275A (zh)
AR (1) AR115770A1 (zh)
AU (1) AU2019301761A1 (zh)
CA (1) CA3106354A1 (zh)
EA (1) EA202190070A1 (zh)
IL (2) IL310297A (zh)
MA (1) MA53128A (zh)
MX (1) MX2021000469A (zh)
SG (1) SG11202012918PA (zh)
TW (1) TW202019910A (zh)
WO (1) WO2020014602A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
PT3664802T (pt) 2017-08-07 2022-05-24 Alkermes Inc Inibidores bicíclicos de histona-desacetilase
CN115243023A (zh) * 2022-07-20 2022-10-25 展讯通信（上海）有限公司 一种图像处理方法、装置、电子设备及存储介质

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
JP2014523857A (ja) 2011-04-28 2014-09-18 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2016018795A1 (en) 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
JP2014523857A (ja) 2011-04-28 2014-09-18 ザ ブロード インスティテュート， インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2016018795A1 (en) 2014-07-28 2016-02-04 The General Hospital Corporation Histone deacetylase inhibitors
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase

Also Published As

Publication number Publication date
SG11202012918PA (en) 2021-02-25
MX2021000469A (es) 2021-06-23
JP2021531335A (ja) 2021-11-18
KR20210031703A (ko) 2021-03-22
MA53128A (fr) 2021-05-19
CN112805275A (zh) 2021-05-14
WO2020014602A1 (en) 2020-01-16
AU2019301761A1 (en) 2021-01-14
IL310297A (en) 2024-03-01
CA3106354A1 (en) 2020-01-16
EP3820863A1 (en) 2021-05-19
TW202019910A (zh) 2020-06-01
JP2024012457A (ja) 2024-01-30
AR115770A1 (es) 2021-02-24
IL279920A (en) 2021-03-01
EA202190070A1 (ru) 2021-10-26
US20210276977A1 (en) 2021-09-09
IL279920B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP7381578B2 (ja) ヒストンデアセチラーゼの二環式阻害剤
TWI417100B (zh) 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
KR102662215B1 (ko) 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
JP4592077B2 (ja) 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−１（ｎｋ−１）アンタゴニストとしての１−アミド−４−フェニル−４−ベンジルオキシメチル−ピペリジン誘導体および関連化合物
CA2570197C (en) Nk1 antagonists
JP2024038202A (ja) ヒストンデアセチラーゼの阻害剤
JP2008543726A (ja) 炎症性疾患の処置のためのｐｇｄ２受容体アンタゴニスト
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
JP2014511355A (ja) ヒストンデアセチラーゼ阻害薬並びにその組成物及び使用方法
JP5412430B2 (ja) ｍＧｌｕ５拮抗薬としての新規複素環系化合物
WO2014146493A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
JP2015528009A (ja) ヒストン脱アセチル化酵素阻害剤ならびにその組成物およびその使用方法
EA039417B1 (ru) Бициклические ингибиторы гистондеацетилазы
JP2022522349A (ja) Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びその使用方法
EA044565B1 (ru) Бициклические ингибиторы гистондеацетилазы
CN106459006B (zh) 2,2,2-三氟乙基-噻二嗪
EA043804B1 (ru) Ингибиторы гистондеацетилазы
JP2022524077A (ja) アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
KR20050023400A (ko) 무스카린 수용체 길항제로서의 아자비시클로 유도체

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231102

R150 Certificate of patent or registration of utility model

Ref document number: 7381578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150